NICE requests explanation from Alexion for price of Soliris for aHUS
The National Institute for Health and Care Excellence (NICE) has issued draft guidance requiring more information from Alexion Pharma to explain the price of �340,200 per adult patient per year when used to treat atypical haemolytic uraemic syndrome (aHUS). At current disease levels the total NHS spend on Soliris (eculizumab) would be �58m in the first year, rising to �80m over five years at predicted diagnosis rates.
Soliris is the first drug to be assessed by NICE through its new highly specialised technologies programme, which is designed to cover drugs for very rare conditions as decided in consultation with the Department of Health.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.